CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
2.480
-0.080 (-3.13%)
At close: Jul 29, 2026, 4:00 PM EDT
2.450
-0.030 (-1.21%)
After-hours: Jul 29, 2026, 5:36 PM EDT
CervoMed Revenue
CervoMed had revenue of $2.09M in the twelve months ending March 31, 2026, down -77.56% year-over-year. In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%.
Revenue (ttm)
$2.09M
Revenue Growth
-77.56%
P/S Ratio
16.20
Revenue / Employee
$139,268
Employees
15
Market Cap
33.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Radiopharm Theranostics | 10.86M |
| Nutriband | 1.80M |
| Hyperion DeFi | 1.04M |
| eXoZymes | -700.00 |
CRVO News
- 15 days ago - CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - GlobeNewsWire
- 20 days ago - CervoMed completes enrollment in neflamapimod study - TheFly
- 20 days ago - CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - GlobeNewsWire
- 23 days ago - CervoMed registers to sell 10.08M shares of common stock for holders - TheFly
- 23 days ago - CervoMed Registration statement: Registration filing - Filings
- 23 days ago - CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 - GlobeNewsWire
- 5 weeks ago - CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 weeks ago - CervoMed announces $10M registered direct offering priced at-the-market - TheFly